MyMD Pharmaceuticals, Inc. announced results from a preclinical study of its investigational cannabinoid Supera-CBD??, a novel, synthetic, non-toxic cannabidiol (CBD) analog. In the study, Supera-CBD targeted and quickly reduced inflammatory pain within 60 minutes, providing pain relief for up to five hours. Comparatively, traditional CBD had no effect on this type of pain in the same study.

According to study researchers at a major academic center where the study was conducted, the results indicate that Supera-CBD may have an effect on the body's TRPV1 pain system channels, which control heat-related pain. Acute pain related to inflammation, burns, and nerve-related pain affects countless individuals worldwide. Supera-CBD has completed genotoxicity studies, and the company has initiated preclinical pain studies in partnership with Johns Hopkins Medicine.

On June 20, 2023, MyMD was issued Japanese Patent No. 7293561 B2, covering Supera-CBD as a new molecular entity, in pharmaceutical formulations, and for use in therapeutic treatments. With this latest issuance, the Company now has 23 issued patents worldwide protecting this drug product candidate, along with two pending applications.